Eupraxia Pharmaceuticals Aktie - EPRX

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

5,89

Gebot

5,80

Fragen

5,95

Volumen

37.833

5,82 Tagesbereich 6,21

3,07 52-Wochen-Bereich 6,49

Marktkapitalisierung

160,691M

Handelsende

6,01

Handelsbeginn

5,99

Letzte Trade

100

5.89

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

28.161

Ausgegebene Aktien

27.282.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-5,63

Gewinn pro Aktie (EPS)

-1,03

Erlöse

Nettogewinn

-28,22M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.eupraxiapharma.com

Hauptsitz

Victoria, British Columbia, Can

Gegründet

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the Toronto Börse with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was $6,01. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of $ 3,07 to $ 6,49.

Eupraxia Pharmaceuticals currently has 27.282.000 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is $163,96 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.63.

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of...

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia Pharmaceuticals Announces CFO Succession PR Newswire VICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is...

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024...

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR...

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR...

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.07	-1.1744966443	5.96	6.21	5.01	23492	5.64107774	CS
4	1.32	28.8840262582	4.57	6.49	4.44	58676	5.15978183	CS
12	1.01	20.6967213115	4.88	6.49	4.13	28161	4.94940485	CS
26	2.48	72.7272727273	3.41	6.49	3.07	28864	4.47955752	CS
52	0.05	0.856164383562	5.84	6.49	3.07	34348	4.15995408	CS
156	4.08	225.414364641	1.81	9.1	0.8	28950	4.37899583	CS
260	-1.86	-24	7.75	9.1	0.8	25295	4.28093935	CS

EPRX - Frequently Asked Questions (FAQ)

What is the current Eupraxia Pharmaceuticals share price?

The current share price of Eupraxia Pharmaceuticals is $ 5,89

How many Eupraxia Pharmaceuticals shares are in issue?

Eupraxia Pharmaceuticals has 27.282.000 shares in issue

What is the market cap of Eupraxia Pharmaceuticals?

The market capitalisation of Eupraxia Pharmaceuticals is CAD 163,96M

What is the 1 year trading range for Eupraxia Pharmaceuticals share price?

Eupraxia Pharmaceuticals has traded in the range of $ 3,07 to $ 6,49 during the past year

What is the PE ratio of Eupraxia Pharmaceuticals?

The price to earnings ratio of Eupraxia Pharmaceuticals is -5,63

What is the reporting currency for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals reports financial results in USD

What is the latest annual profit for Eupraxia Pharmaceuticals?

The latest annual profit of Eupraxia Pharmaceuticals is USD -28,22M

What is the registered address of Eupraxia Pharmaceuticals?

The registered address for Eupraxia Pharmaceuticals is 201 - 2067 CADBORO BAY ROAD, VICTORIA, BRITISH COLUMBIA, V8R 5G4.

What is the Eupraxia Pharmaceuticals website address?

The website address for Eupraxia Pharmaceuticals is www.eupraxiapharma.com

Which industry sector does Eupraxia Pharmaceuticals operate in?

Eupraxia Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
VRTSVertiqal Studios Corporation	$ 0,025 (25,00%)	19k
RTGRTG Mining Inc	$ 0,025 (25,00%)	51k
MNOMeridian Mining UK Societas	$ 0,58 (19,59%)	3,18M
VRNVeren Inc	$ 8,20 (16,15%)	27,27M
EXROExro Technologies Inc	$ 0,125 (13,64%)	530,75k
GMTNGold Mountain Mining Corp	$ 0,015 (-25,00%)	3,04M
AMMAlmaden Minerals Ltd New	$ 0,09 (-21,74%)	36,65k
AUMNGolden Minerals Company	$ 0,13 (-21,21%)	258,62k
QETH.UThe Ether Fund	US$ 29,69 (-19,17%)	2,12k
XLYAuxly Cannabis Group Inc	$ 0,07 (-17,65%)	5,05M
VRNVeren Inc	$ 8,20 (16,15%)	27,27M
WCPWhitecap Resources Inc	$ 7,99 (-14,55%)	25,51M
MFCManulife Financial Corporation	$ 41,22 (-2,04%)	22,18M
CNQCanadian Natural Resources Ltd	$ 40,93 (0,47%)	17,75M
ENBEnbridge Inc	$ 61,64 (2,09%)	14,4M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eupraxia Pharmaceuticals Inc (EPRX)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Eupraxia Pharmaceuticals Inc

EPRX Neueste Nachrichten

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

EPRX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eupraxia Pharmaceuticals Inc (EPRX) Börsenkurse

Eupraxia Pharmaceuticals Inc (EPRX)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Eupraxia Pharmaceuticals Inc

EPRX Neueste Nachrichten

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces CFO Succession

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

EPRX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen